Esmya

Esmya is a brand name for ulipristal acetate, a medication used primarily for the treatment of uterine fibroids. Uterine fibroids are non-cancerous growths that develop in the uterus. Esmya is a selective progesterone receptor modulator (SPRM). It works by binding to progesterone receptors in the body, which can help to reduce the size of uterine fibroids and control heavy menstrual bleeding associated with them.

The medication is taken orally and is typically prescribed for short-term treatment before surgery to remove fibroids or for long-term management of symptoms. It is not intended for use by pregnant or breastfeeding women, or individuals with a history of certain medical conditions. The use of Esmya has been associated with a risk of liver injury, and its use has been restricted in some regions. Healthcare providers carefully assess the potential benefits and risks before prescribing Esmya and monitor patients for any signs of adverse effects, particularly liver function. Alternative treatments for uterine fibroids exist, and the choice of therapy depends on individual patient factors and the severity of the condition.